Delivery Order SPE2DB22D2206-SPE2DB25FFE30

Award Date 1/20/25
Potential Completion Date 1/21/25
Potential Value $7.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $2,655.32, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is a delivery order for 4566964538 - RAMELTEON 8 MG TABLET UD 50S, with an ultimate completion date of January 17, 2025. It is a firm fixed-price contract, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,689.83 Firm Fixed Price Delivery Order is for the supply of 4561454598 - RAMELTEON 8 MG TABLET 30S. The contract has an ultimate completion date of July 11, 2023 and was awarded on July 10, 2023. This award is associated with a larger $999,999,999 Indefinite Delivery Contract (IDC) held by...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,488.56 firm fixed-price delivery order covers the supply of Ramelteon 8 mg tablets for the DLA Troop Support Medical program. The contract has a period of performance through November 27, 2024 and was not designated with a set-aside requirement, indicating open competition. Amerisourcebergen holds a...
This federal contract award, SPE2DB20D1100|SPE2DB25FZ68D, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp. The contract is for the delivery of RAMELTEON 8 MG TABLET 30S, a pharmaceutical product. The contract has a firm fixed price of $1,061.28 and a completion date of December 20, 2024. This is a delivery order contract, and no set-aside designation was used. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,212.24 firm fixed-price delivery order is for the supply of Ramelteon 8 MG Tablet UD 50S, a medication used to treat insomnia. The award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026....
The Department of Defense's Defense Logistics Agency awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to supply 50 units of the pharmaceutical RAMELTEON 8 MG TABLET UD. The $1,999.20 contract has a performance period ending January 11, 2024. AmerisourceBergen Drug Corp, which provides pharmaceutical products and services to U.S. government agencies, including the Department of Defense, has received numerous federal...
This federal contract award, valued at $4,187.54, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order for the supply of Ambien CR 12.5 mg tablets. The award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves...
This federal contract award, valued at $7,665.30, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of AMBIEN CR 6.25 MG TABLET 100S. The $7,874.89 firm fixed-price delivery order contract has a completion date of May 23, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award, valued at $2,749.75, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of AMBIEN CR 6.25 MG TABLET 100S, a prescription medication, to support military healthcare programs. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical....
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB25FFE30
    Delivery Order

This federal contract award, valued at $7,695.20, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RAMELTEON 8 MG TABLET UD 50S, a prescription medication.

The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

In addition to the DLA contract, Amerisourcebergen also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 4/21/25, 11:09 AM